ABBV Stock Recent News
ABBV LATEST HEADLINES
Many S&P 500 Dividend Aristocrats remain overvalued, but select high-yield 'Dogs' like Realty Income and Amcor offer attractive entry points for income investors. Analyst forecasts suggest the top ten Aristocrat Dogs could deliver 16% to 38% net gains by May 2026, with average risk below the market. Caution: Fourteen Aristocrats have negative free cash flow margins, making their dividends less secure despite high yields—focus on 'safer' picks like Hormel.
NEW YORK , May 20, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cerevel Therapeutics Holdings, Inc. investors who were adversely affected by alleged securities fraud.
NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit.
NEW YORK , May 19, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Dividend stocks are a foundational building block for creating a retirement portfolio, offering a reliable income stream and potential for capital appreciation.
NEW YORK, NY / ACCESS Newswire / May 19, 2025 / If you suffered a loss on your Cerevel Therapeutics Holdings, Inc. (NYSE:ABBV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cerevel-therapeutics-holdings-inc-lawsuit-submission-form?prid=149127&wire=1 or contact Joseph E. Levi, Esq.
Dividend stocks can be a smart way to generate steady income, especially in uncertain markets. However, not all dividend payers are created equal.
Make money without even trying: That's what passive income is all about. But good investment alternatives are required to make this "easy" money.
NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit.
AbbVie (NYSE:ABBV) stock has garnered recent attention following the FDA approval of Emrelis for adults with previously treated lung cancer who exhibit an overabundance of the c-Met protein. This protein is known to promote tumor growth and resistance to certain therapies.